Granulocyte colony-stimulating factor (G-CSF or GCSF) is a secreted glycoprotein that stimulates the proliferation and differentiation of granulocyte precursor cells, and induces mobilization of peripheral blood progenitor cells from the bone marrow. Development of recombinant human G-CSF has had a profound impact on the treatment of many diseases, including severe chronic neutropenia and cancer, and has enabled peripheral stem cell transplantation to supplant bone marrow transplantation in the autologous setting. This Milestones in Drug Therapy volume describes the experience of the last 20 years of treatment with recombinant human G-CSF, including the basic science, the use of recombinant human G-CSF in both the oncology and nononcology settings, and the safety and economics of its use. Many of the authors were the original investigators of recombinant human G-CSF and other authors are key researchers who provide their outlook for the next 20 years for use of and research with recombinant human G-CSF.

Granulocyte colony-stimulating factor (G-CSF or GCSF) is a secreted glycoprotein that stimulates the proliferation and differentiation of granulocyte precursor cells, and induces mobilization of peripheral blood progenitor cells from the bone marrow. Development of recombinant human G-CSF has had a profound impact on the treatment of many diseases, including severe chronic neutropenia and cancer, and has enabled peripheral stem cell transplantation to supplant bone marrow transplantation in the autologous setting. This Milestones in Drug Therapy volume describes the experience of the last 20 years of treatment with recombinant human G-CSF, including the basic science, the use of recombinant human G-CSF in both the oncology and nononcology settings, and the safety and economics of its use. Many of the authors were the original investigators of recombinant human G-CSF and other authors are key researchers who provide their outlook for the next 20 years for use of and research with recombinant human G-CSF.

This second edition is a one-source guide to current information about red blood cell physiology and the action of native and recombinant human erythropoietic factors. Topics in the fields of erythropoiesis, recombinant protein discovery and production, and treatment of patients with anemia due to renal failure, cancer, or chronic diseases are covered. The newest theories in erythropoiesis (receptors, signaling), manufacturing, new formulations, and clinical research are discussed.

This book is of interest to researchers and clinical investigators in academia and biotechnology and pharmaceutical companies, to clinical research associates, clinical monitors, and physician investigators.

A comprehensive one-source guide to the most current information on red blood cell formation and the action of recombinant human erythropoietins. Topics covered include: erythropoiesis, recombinant protein discovery and production, and treatment of patients with anemia. The newest theories in erythropoiesis (receptors, signaling), manufacturing, new formulations, and clinical research are discussed. The text is ideal for researchers and clinical investigators in academia, biotechnology, and pharmaceutical companies, as well as clinical research associates, clinical monitors, and physician investigators. This softcover volume is an unchanged second printing of the hardcover edition published in 2003.